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Abstract
Background: Most guidelines have been proposing, for more than 15 years, a b-lactam combined with either a
quinolone or a macrolide as empirical, first-line therapy of severe community acquired pneumonia (CAP) requiring
ICU admission. Our goal was to evaluate the outcome of patients with severe CAP, focusing on the impact of new
rather than old fluoroquinolones combined with b-lactam in the empirical antimicrobial treatments.
Methods: Retrospective study of consecutive patients admitted in a 16-bed general intensive care unit (ICU),
between January 1996 and January 2009, for severe (Pneumonia Severity Index > or = 4) community-acquired
pneumonia due to non penicillin-resistant Streptococcus pneumoniae and treated with a b-lactam combined with a
fluoroquinolone.
Results: We included 70 patients of whom 38 received a b-lactam combined with ofloxacin or ciprofloxacin and
32 combined with levofloxacin. Twenty six patients (37.1%) died in the ICU. Three independent factors associated
with decreased survival in ICU were identified: septic shock on ICU admission (AOR = 10.6; 95% CI 2.87-39.3; p =
0.0004), age > 70 yrs. (AOR = 4.88; 95% CI 1.41-16.9; p = 0.01) and initial treatment with a b-lactam combined with
ofloxacin or ciprofloxacin (AOR = 4.1; 95% CI 1.13-15.13; p = 0.03).
Conclusion: Our results suggest that, when combined to a b-lactam, levofloxacin is associated with lower mortality
than ofloxacin or ciprofloxacin in severe pneumococcal community-acquired pneumonia.
Background
Streptococcus pneumoniae is the leading causative agent
of community-acquired pneumonia (CAP). Despite new
antimicrobial agents and advances in supportive measures,
attributable mortality linked to pneumococcal pneumonia
remains unchanged and dramatically high when patient
are admitted in intensive care units (ICU) [1].
Most guidelines have been proposing, for more than
15 years, a combination of a b-lactam with either a qui-
nolone or a macrolide as empirical, first-line therapy of
severe CAP requiring ICU admission [2-8]. Although a
recent study demonstrated combination antibiotic ther-
apy to be associated with a higher survival rate than
monotherapy in patients with severe CAP and shock [9],
the rationale for this combination was not to increase
efficacy but rather to routinely provide coverage of all
common pathogens causing severe CAP and particu-
larly, S. pneumoniae and Legionella species.
In our ICU, we followed until 2003 the 1991 French
recommendations [2]. Most patients received an empiri-
cal therapy based on a b-lactam-fluoroquinolone combi-
nation. Before 2003, fluoroquinolones used were
ofloxacin and ciprofloxacin. Levofloxacin replaced these
quinolones since its 2003 addition to the hospital for-
mulary. Such a replacement was comforted by the ERS,
French and IDSA guidelines published between 2005
and 2007 [6-8]. We wished to determine outcomes of
patients treated with a combination of b-lactam plus
fluoroquinolone for severe pneumococcal pneumonia.
This homogenous modification of severe CAP antibiotic
management in our ICU gives us the further opportu-
nity to assess the influence of a fluoroquinolone with
enhanced activity against S.pneumoniae.
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Methods
Patients
Firstly, we retrospectively collected all consecutive
patients aged > 18 years who were admitted into our
ICU (16-bed medical and surgical intensive care unit in
a 450-bed general hospital) between January 1996 and
January 2009 for severe community-acquired pneumonia
(CAP) and who received a definite diagnosis of pneumo-
coccal pneumonia. Secondly, we selected patients who
received, as initial antibiotic treatment, a b-lactam plus
a fluoroquinolone, used with an appropriate dosage by
IV route. Thirdly, patients were divided into two groups
according to the fluoroquinolone used, Group A for
ofloxacin or ciprofloxacin, Group B for levofloxacin.
The study protocol was submitted to the Institutional
Review Board for University Hospital of Lille which gave
an approval with waiver of informed consent, in agree-
ment with French regulations concerning such retro-
spective studies.
CAP was defined by the following criteria observed at
initial presentation or occurring within 48 h following
hospitalization: acute onset of signs and symptoms of
lower respiratory tract infection and a new pulmonary
infiltrate found on the hospital admission chest radio-
graph. We excluded patients coming from nursing
homes or hospitalized within 90 days prior to develop-
ing pneumonia or hospitalized > 48 h in general medical
wards before ICU admission, and those with radio-
graphic abnormalities attributed solely to any other
known cause (i.e., pulmonary embolus, lung carcinoma
or congestive heart failure). The decision for admission
to our ICU was made, in all cases, by the attending phy-
sicians. However, only patients having a Pneumonia
Severity Index (PSI) score ≥ 4 were included in this
study [10].
Streptococcus pneumoniae was considered as the
causative agent of CAP when a S. pneumoniae strain was
isolated from > 1 blood culture or when validated
sputum (< 10 squamous epithelial cells and > 25 poly-
morphonuclear cells per low-power field) or tracheo-
bronchial aspirates cultures grew with > 105 cfu/mL
S. pneumoniae. Patients having CAP due to a penicillin-
resistant strain of S. pneumoniae (MIC > 2 mg/l) were
excluded from our study.
Appropriate drug dosages were defined in the French
recommendations as: amoxicillin > 50 mg/kg/d, cefotax-
ime > 50 mg/kg/d, ceftriaxone > 20 mg/kg/d, piperacillin
> 200 mg/kg/d, ofloxacin = 200 mg/12 h, ciprofloxacin =
400 mg/12 h, levofloxacin = 500 mg/12 h [2,3,7]. These
drug dosages for b-lactams, ofloxacin and ciprofloxacin
were unchanged during the study period. Thus, doses
used in both groups were similar.
Data collection, evaluation and definition
Within 24 h of admission, all patients underwent
clinical, radiological and biological tests. Briefly, we
recorded age, gender, underlying clinical characteristics
and initial vital signs. Chronic respiratory insufficiency
was assessed combining the usual clinical and radiolo-
gical criteria and the coexistence of ventilatory impair-
ment assessed either before or after ICU stay.
Immunosuppression was defined as recent use of
immunosuppressant or systemic corticosteroids (i.e.,
prednisolone > 0.5 mg/kg/day for more than 1 month),
human immunodeficiency virus infection, neutropenia
(absolute neutrophil count < 1.000 cells/mm3), organ
transplantation with ongoing immunosuppressant,
cancer chemotherapy within the past 3 months, or
asplenia. Shock was defined as a sustained (> 1 h)
decrease in the systolic blood pressure of at least
40 mm Hg from baseline or a resultant systolic blood
pressure < 90 mm Hg after adequate volume replace-
ment and in the absence of any antihypertensive drug
[11]. Severity of illness at admission to ICU was
assessed using the Simplified Acute Physiology Score II
(SAPS) II [12], the Sepsis-related Organ Failure Assess-
ment (SOFA) score [13] and the logistic organ dys-
function (LOD) score [14]. We also calculated the PSI
at ICU admission [10]. For all patients, information on
the following therapeutic topics instituted within
48 hours following ICU admission was recorded: sup-
portive measures such as mechanical ventilation or
hemodialysis, use of vasopressor drugs, hydrocortisone,
drotrecogin alfa (activated), or intensive insulin ther-
apy. The effectiveness of initial antimicrobial therapy
was assessed within 72 h after treatment as follows:
A lack of clinical improvement 3 days after treatment
initiation (worsening or persistent fever or hypother-
mia, worsening of pulmonary infiltrates or of respira-
tory function assessed by PaO2/FiO2) defined an
ineffective treatment. On day 3, day 5 and day 7, body
temperature, and SOFA score were determined. During
the patient’s stay in the ICU, occurrence of complica-
tions was recorded. We distinguished sepsis-related
complications (secondary septic shock, acute respira-
tory distress syndrome or development of multiple
organ failure), hospital-acquired lower respiratory tract
(HA-LRT) superinfections and ICU-related complications
(i.e., upper gastrointestinal bleeding, catheter-related infec-
tion, deep venous thrombosis and pulmonary embolism).
Multiple organ failure (MOF), acute respiratory distress
syndrome (ARDS) and HA-LRT were defined according
to usual criteria [15-17]. Durations of mechanical ventila-
tion, treatment with vasopressor drugs, and ICU length of
stay were noted.
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Finally, patient mortality was evaluated on D-15, and
at the time of ICU discharge.
Methods of analysis
Descriptive analyses were performed in order to check
and resume data. Characteristics of patients in each
group were compared. Continuous variables were com-
pared using the Student’s t test. Categorical variables
were compared using Chi-square test or Fisher’s exact
test when Chi-square was not appropriate. Differences
between groups were considered to be significant for
variables yielding a p value < 0.05. A stepwise logistic
regression including variables collected within the first
48 hours of ICU stay and associated with a p value
< 0.15 in bivariate analysis was performed. Adjusted
odd-ratios were computed using a logistic regression
analysis including the independent predictors of mortal-
ity. The Kaplan-Meier product limit method and the
log-rank test were used to construct and compare survi-
val curves for patients in each group.
All statistical analyses were performed using the SAS
Software, V9.1.
Results
During the study period, 378 patients with severe CAP
were admitted in our unit. Among them, 83 (22%) patients
exhibited a severe pneumococcal pneumonia and, finally,
we identified 70 patients treated with a b-lactam combined
with a fluoroquinolone, including 53 men (75.7%) and
17 women (24.3%). The mean age was 63.8 ± 16.8 years.
S. pneumoniae was identified in blood cultures in 25
patients (35.7%). Infection was polymicrobial in 18 patients
(25.7%). Causative pathogens associated with S. pneumo-
niae were Haemophilus influenzae (n = 7), methicillin sus-
ceptible Staphylococcus aureus (n = 4), enterobacteriaceae
(n = 4), Streptococcus spp. (n = 2) and Moraxella catarrha-
lis (n = 2). All pathogens were susceptible to at least one
drug (b-lactam and/or fluoroquinolone) received by the
patients. Thirty-eight patients (54.3%) were classified as
Group A. b-lactams used were a third generation
cephalosporin (n = 20; 52.6%), amoxicillin ± clavulanic
acid (n = 16; 42.1%) and piperacillin-tazobactam (n = 2;
5.3%) combined with ofloxacin (n = 33; 86.8%) or cipro-
floxacin (n = 5; 13.2%). Thirty-two patients (45.7%) were
classified as Group B. b-lactams used were a third genera-
tion cephalosporin (n = 26; 81.3%), amoxicillin ± clavula-
nic acid (n = 5; 15.6%) and piperacillin-tazobactam (n = 1;
3.1%) combined with levofloxacin.
Main patients’ characteristics on ICU admission are
reported Table 1. Most characteristics were similar in
the two groups. However, underlying chronic respiratory
insufficiency and bacteremia were more frequent in
Group B patients.
Main therapeutics instituted during ICU stay, evolu-
tion of severity scores, and occurrence of complications
are reported Table 2. The most significant differences
between the two groups of patients were the more
frequent use of drotrecogin alpha, intensive insulin
therapy and hydrocortisone in Group B patients.
On Day 15, 14 (20%) patients had died, 12 (31.6%) in
Group A and 2 (6.3%) in Group B (p = 0.02).
Table 1 Characteristics of patients with severe pneumococcal pneumonia on ICU admission*
Characteristics Overall population n = 70 Group A n = 38 Group B n = 32 p
Age (years) 63.8 ± 16.8 63.5 ± 16.5 64.1 ± 17.4 0.87
Male 53 (75.7%) 30 (78.9%) 23 (71.9%) 0.49
Female 17 (24.3%) 8 (21.1%) 9 (28.1%)
Malignancy 5 (7.1%) 3 (7.9%) 2 (6.3%) 0.70
Diabetes mellitus 11 (15.7%) 4 (10.5%) 7 (21.8%) 0.19
Chronic heart failure 11 (15.7%) 5 (13.1%) 6 (18.7%) 0.52
Chronic respiratory insufficiency 12 (17.1%) 3 (7.9%) 9 (28.1%) 0.02
Immunosuppression 13 (18.5%) 9 (23.6%) 4 (12.5%) 0.23
SAPS II 52.9 ± 19.5 53.3 ± 20.3 52.5 ± 18.9 0.86
LOD score 7.3 ± 4.0 7.6 ± 4.0 6.8 ± 4.0 0.40
SOFA score 8.3 ± 3.9 9.0 ± 4.1 7.5 ± 3.5 0.10
PSI 4 21 (30%) 14 (36.8%) 7 (21.9%) 0.17
PSI 5 49 (70%) 24 (63.2%) 25 (78.1%)
Temperature (°C) 37.9 ± 1.5 38.2 ± 1.4 37.5 ± 1.5 0.04
ARF requiring MV 55 (78.5%) 30 (78.9%) 25 (78.1%) 0.93
Septic shock 34 (48.5%) 17 (44.7%) 17 (53.1%) 0.48
Bacteremia 25 (35.7%) 9 (23.6%) 16 (50%) 0.02
*Data are presented as No. (%) or mean ± SD.
MV: mechanical ventilation; SAPS: simplified acute physiology score; LOD score: logistic organ dysfunction score: SOFA: Sepsis-related Organ Failure Assessment
score; PSI: Pneumonia Severity Index; ARF: Acute Respiratory Failure.
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Overall, 26 patients died in the ICU, 17 (44.8%) in
group A vs. 9 (28.1%) in group B (p = 0.15). So, differ-
ence in mortality rates was only significant during the
first 15 days of ICU stay (Figure 1). In Group A, in-ICU
mortality was 45% (9/20) when ofloxacin or ciprofloxa-
cin were combined with a third generation cephalos-
porin and 44.4% (8/18) when combined with another
beta-lactam, respectively (p = 0.97). In group B, it was
26.9% (7/26) when levofloxacin was combined with a
third generation cephalosporin and 33.3% (2/6) when
combined with another beta-lactam (p = 1).
Results of ICU-discharge survival prognosis bivariate
analysis, including factors present on ICU admission,
are reported Table 3. All underlying diseases (excepted
chronic heart failure), mechanical ventilation, use of a
third generation cephalosporin combined with a fluoro-
quinolone, and bacteraemia on ICU admission did not
appear as significant prognostic variables in this analysis.
Among the 25 bacteremic patients, mortality was higher
in group A patients (66.6%) than group B patients
(31.3%), but the difference was not statistically signifi-
cant (6/9 vs. 5/16; p = 0.11). Among the 34 patients
with septic shock on ICU admission, mortality was
higher in group A patients (71%) than in Group B
patients (47%), but the difference was not statistically
significant (8/17 vs. 12/17; p = 0.30).
Among variables collected during the ICU stay, use of
hydrocortisone, intensive insulin therapy, haemodialysis
and occurrence of HA-LRT superinfections did not appear
as significant prognostic variables. Conversely, improve-
ment on D3, SOFA > 8 on D3, D5, and D7, and occur-
rence of sepsis-related complications were significantly
associated with outcome at ICU discharge (Table 4).
According to the results of the bivariate analysis, the
following variables were entered in the stepwise analysis:
chronic heart failure, age > 70 yrs, acute respiratory fail-
ure requiring mechanical ventilation, septic shock on
ICU admission, use of hydrocortisone, haemodialysis,
PSI score = 5, SAPS II > 50 on D1, LOD > 8 on D1,
Table 2 Therapeutics data and evolution during ICU stay of patients with severe pneumococcal pneumonia*
Characteristics Overall population n = 70 Group A n = 38 Group B n = 32 P
Cephalosporin in initial treatment 46 (65.7%) 20 (52.6%) 26 (81.3%) 0.01
Use of drotrecogin alpha 4 (5.7%) 0 4 (12.5%) 0.02
Intensive insulin therapy 30 (42.8%) 4 (10.5%) 26 (81.2%) <0.0001
Use of hydrocortisone 24 (34.3%) 6 (15.7%) 18 (56.3%) 0.0004
Haemodialysis 10 (14.3%) 3 (7.8%) 7 (21.8%) 0.09
Body temperature on D3 37.4 ± 1.3 37.8 ± 1.0 36.9 ± 1.3 0.0008
SOFA score on D3 7.5 ± 4.8 8.0 ± 5.1 7.1 ± 4.5 0.48
Improvement on D3 43 (61.4%) 20 (52.6%) 23 (71.8%) 0.09
Body temperature on D5 37.5 ± 0.9 37.7 ± 0.9 37.3 ± 0.9 0.22
SOFA score on D5 6.4 ± 4.8 7.5 ± 4.9 5.5 ± 4.5 0.13
Body temperature on D7 37.4 ± 1.0 37.7 ± 0.9 37.0 ± 1.0 0.04
SOFA score on D7 6.6 ± 5.0 7.7 ± 5.0 5.6 ± 4.8 0.17
Sepsis-related complications 31 (44.3%) 16 (42.1%) 15 (46.8%) 0.68
HA-LRT superinfections 17 (24.3%) 7 (18.4%) 10 (31.2%) 0.21
ICU-related complications 12 (17.1%) 8 (21.0%) 4 (12.5%) 0.34
Duration of MV (days) 11.3 ± 14.3 11.2 ± 15.6 11.5 ± 12.9 0.93
Duration of vasopressor use (days) 3.5 ± 4.8 3.6 ± 5.6 3.3 ± 3.9 0.80
LOS in ICU (days) 14.6 ± 16.3 14.5 ± 19.0 14.6 ± 12.6 0.97
Mortality on D-15 14 (20%) 12 (31.6%) 2 (6.3%) 0.02
Mortality in ICU 26 (37.1%) 17 (44.8%) 9 (28.1%) 0.15
*Data are presented as No. (%) or mean ± SD.
MV: mechanical ventilation; SAPS: simplified acute physiology score; LOD score: logistic organ dysfunction score: SOFA: Sepsis-related Organ Failure Assessment
score; PSI: Pneumonia Severity Index; HA-LRT superinfections: hospital-acquired lower respiratory tract superinfections; LOS = length of stay.
Figure 1 15-day survival curves in patients treated with b-
lactam combined with levofloxacin versus b-lactam combined
with ofloxacin or ciprofloxacin. Log rank test: p = 0.031.
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SOFA >8 on D1 and initial treatment with a b-lactam
combined with ofloxacin or ciprofloxacin (Group A).
Three independent factors associated with outcome at
ICU discharge were identified: septic shock on ICU admis-
sion (AOR = 10.6; 95% CI 2.87- 39.3; p = 0.0004), age > 70
yrs. (AOR = 4.88; 95% CI 1.41-16.9; p = 0.01) and initial
treatment with a b-lactam combined with ofloxacin or
ciprofloxacin (AOR = 4.1; 95% CI 1.13-15.13; p = 0.03).
Discussion
The main finding of this retrospective analysis is that
levofloxacin plus a b-lactam appears to be associated
with improved survival compared to ofloxacin or cipro-
floxacin plus a b-lactam in severe pneumococcal CAP.
Empirical antibiotic regimen for ICU-treated severe
CAP has long been recommended to cover the 3 most
common severe CAP pathogens (S. pneumoniae,
S. aureus and H.influenzae), atypical pathogens and most
relevant Enterobacteriaceae species. Levofloxacin is a
fluoroquinolone active against most of these pathogens,
especially S. pneumoniae with or without decreased peni-
cillin susceptibility [18,19]. Its clinical activity in CAP has
been well documented in various clinical trials in Europe
and the USA [20,21]. Some studies demonstrated the effi-
cacy of levofloxacin used as monotherapy in severe CAP,
compared to ceftriaxone plus erythromycin or cefotaxime
plus ofloxacin [22,23]. Nevertheless, experts continue to
propose, for ICU-treated severe CAP, an empirical anti-
biotic regimen based on an anti pneumococcal b-lactam
combined with either a macrolide or a fluoroquinolone.
Since respiratory fluoroquinolones with enhanced activity
against S. pneumoniae (levofloxacin, moxifloxacin or
gemifloxacin) became available, they replaced second
generation fluoroquinolones (ofloxacin or ciprofloxacin)
in the guidelines [6-8]. This fluoroquinolone generation
shift has never been clearly justified and, to our knowl-
edge, no clinical study has compared these different qui-
nolones combined with a b-lactam in severe CAP. Our
results suggest that, when severe CAP causative agent is
S. pneumoniae, a combination levofloxacin plus b-lactam
is associated with lower mortality than a combination
ofloxacin or ciprofloxacin plus b-lactam.
These results could be surprising as all patients
received an appropriately dosed b-lactam active against
S. pneumoniae and as numerous strains of S. pneumoniae
Table 3 Bivariate analysis of variables collected on D1 influencing the outcome, at ICU discharge, of pneumococcal
CAP*
Variables Survivors n = 44 Non survivors n = 26 p
Age > 70 yrs. 14 (31.8%) 16 (61.6%) 0.01
Gender: Male/Female 33/11 20/6 0.85
Malignancy 4 (9.0%) 1 (3.8%) 0.41
Diabetes mellitus 7 (15.5%) 4 (15.4%) 0.95
Chronic heart failure 4 (9.1%) 7 (26.9%) 0.04
Chronic respiratory insufficiency 8 (18.2%) 4 (15.4%) 0.76
Immunosuppression 10 (22.7%) 3 (11.5%) 0.24
SAPS II >50 18 (40.1%) 19 (73.1%) 0.009
LOD >8 13 (29.5%) 16 (61.6%) 0.008
SOFA >8 14 (31.8%) 18 (69.3%) 0.002
PSI 4/5 17/27 4/22 0.04
MV on D1 32 (72.7%) 23 (88.4%) 0.12
Septic shock 14 (31.8%) 20 (76.9%) 0.0003
Bacteremia 14 (31.8%) 11 (42.3%) 0.37
Patients in Group A/Group B 21/23 17/9 0.15
Cephalosporin in initial treatment 30 (68.2%) 16 (61.6%) 0.57
*Data are presented as No. (%).
MV: mechanical ventilation; SAPS: simplified acute physiology score; LOD score: logistic organ dysfunction score: SOFA: Sepsis-related Organ Failure Assessment
score; PSI: Pneumonia Severity Index.
Table 4 Bivariate analysis of variables collected during







Use of hydrocortisone 12 (27.3%) 12 (46.2%) 0.1
Intensive insulin therapy 18 (40.9%) 12 (46.2%) 0.66
Haemodialysis 6 (13.6%) 4 (15.4%) 0.1
Improvement on D3 36 (81.8%) 7 (26.9%) <0.0001
SOFA >8 on D3 9 (20.5%) 14 (53.8%) <0.0001
SOFA >8 on D5 10 (22.7%) 14 (53.8%) 0.0001
SOFA >8 on D7 10 (22.7%) 13 (50%) 0.009
Sepsis-related complications 14 (31.8%) 17 (65.4%) 0.006
HA-LRT superinfections 8 (18.2%) 9 (34.6%) 0.12
*Data are presented as No. (%).
SOFA: Sepsis-related Organ Failure Assessment score; HA-LRT superinfections:
hospital-acquired lower respiratory tract superinfections.
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remain in vitro susceptible to ofloxacin or ciprofloxacin.
However, there might be bacteriological and clinical data
explaining our results. A synergy between b-lactams and
levofloxacin against S. pneumoniae has been reported
[24]. Conversely, synergy was rarely observed between
the combination of cefotaxime and ofloxacin [25]. Recent
clinical studies suggest that combination therapies could
improve the prognosis of pneumococcal pneumonia:
Waterer et al. retrospectively studying 225 patients with
severe bacteremic pneumococcal pneumonia demon-
strated that a single effective therapy was an independent
predictor of mortality (AOR = 6.2) [26]. Baddour et al.
performed a prospective, multicenter, international study
including 844 adult patients with S. pneumoniae bactere-
mia [27]. Although the 14-day mortality was not signifi-
cantly different for all patients receiving monotherapy
versus combination (11.5% vs. 10.4%), a combination of
in vitro active agents was associated with a significantly
lower mortality than a single active agent (19.4% vs. 60%;
p = 0.0006).
The present work has numerous limits. The most
important is probably major treatment differences
among the two groups. Patients were recruited during
a long period (1996-2009), during which therapies
such as hydrocortisone, drotrecogin alfa (activated), or
intensive insulin therapy were introduced. Manage-
ment of septic shock and ARDS has changed following
results of large international studies [28,29]. As most
changes in management of patients with multiple
organ failures overlap with our antibiotic policy
changes, our results might be biased. Indeed, hydrocor-
tisone use and intensive insulin therapy were more fre-
quent in group B than in Group A. However, these
factors were not significantly associated with ICU sur-
vival in bivariate analysis and hydrocortisone use, in
multivariate analysis, was not an independent prognos-
tic factor. Moreover, there is no evidence suggesting a
survival benefit by most adjunctive therapies in
patients with CAP [30] and the benefit of intensive
insulin therapy in medical ICU and/or low-dose ster-
oids is now highly questionable [31,32]. Similarly, the
use of cephalosporin is more frequent in group B than
in group A. However, the use of a third generation
cephalosporin rather than amoxicillin has no impact
on prognosis. This is not surprising as, to our knowl-
edge, no clinical study demonstrated a third generation
cephalosporin to be superior to amoxicillin for non
penicillin-resistant S. pneumoniae CAP as far as drug
dosage is adequate. Finally, some important prognostic
parameters such as the time elapsed between admis-
sion and the first dose of antibiotic were not taken
into account in our study. Before 2006, we did not
have computerized data charts thus, exact time of
admission and antibiotics admission, particularly for
patients transferred from other departments/hospitals
cannot be obtained.
Conclusions
Our study suggests that levofloxacin combined with a
b-lactam is associated with improved survival in com-
parison with ofloxacin or ciprofloxacin combined with a
b-lactam in severe pneumococcal patients admitted in
the ICU. This combination, proposed by current guide-
lines as empirical treatment of severe CAP patients
admitted in ICU could improve their prognosis.
Obviously, only a prospective, randomized, double-blind
trial could confirm this result.
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